Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 1,162 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,162 shares of the stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total transaction of $495,407.08. Following the transaction, the insider directly owned 104,742 shares in the company, valued at approximately $44,655,704.28. The trade was a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, October 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $410,060.00.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $414.22, for a total transaction of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80.

Natera Trading Up 2.7%

NTRA stock traded up $11.58 during trading on Thursday, hitting $436.00. The stock had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The company’s 50-day moving average price is $375.27 and its two-hundred day moving average price is $265.54.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same period in the previous year, the business earned ($0.74) EPS. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. On average, sell-side analysts anticipate that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the subject of several research reports. BTIG Research boosted their price target on Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research report on Tuesday. Stephens lifted their target price on shares of Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Canaccord Genuity Group lifted their target price on shares of Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Roth Capital began coverage on shares of Natera in a report on Thursday, October 22nd. They set a “buy” rating and a $475.00 target price for the company. Finally, UBS Group increased their target price on shares of Natera from $290.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Natera in the second quarter valued at approximately $2,962,770,000. Bank of America Corp DE purchased a new position in Natera during the second quarter worth approximately $199,960,000. Legal & General Group Plc purchased a new position in Natera during the second quarter worth approximately $150,143,000. Bank of New York Mellon Corp acquired a new position in Natera during the second quarter worth $149,278,000. Finally, Avala Global LP acquired a new position in Natera during the second quarter worth $124,867,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.